Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutica...( Research by CMR Shows Revenue Derived...),Health

Research by CMR Shows Revenue Derived from New Products Launched within the

Last Five Years has Dropped to Just 16% of Total Revenue in 2006

PHILADELPHIA, Aug. 15 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today issued its quarterly The Ones-to-Watch report, providing expert insight into the five most promising drugs to enter each new phase of clinical development between April and June 2007.

"This quarter's most promising drugs all have significant market potential and are associated with diseases and conditions that impact countless numbers of individuals," said Peter Robins, PhD, and editorial content manager, Thomson Scientific. "These important clinical developments are highly encouraging for innovation-based companies in a period when many pharmaceutical products are coming toward the end of their patent protection."

New research from CMR, a Thomson company, shows that revenue derived from new products (those launched within the last five years) dropped to just 16% of total revenue in 2006. And although the cost of research and development continues to rise, there is no sign of a sustained upturn in the number of new products reaching the market.

Which are the Ones-to-Watch this Quarter?

Topping this quarter's approval list is Novartis Vaccines & Diagnostics' Optaflu(R), a vaccine for influenza derived from a novel, proprietary cell line. Approved for use in the EU in June 2007, Novartis plans to file for US approval of Optaflu in 2008.

Second on our list is Wyeth, which is marketing Lybrel(TM) -- a combination of Levono
'/>"/>

SOURCE Thomson Scientific Copyright©2007 PR Newswire.

0 GOOD